Physician profile
Roger Enos Smith
NPI 1356361380
$649.46
in general payments reported to CMS, 2019-2025
15 companies · $97.92 in 2025
The $97.92 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.69 · 2020: $26.38 · 2022: $178 · 2023: $198 · 2024: $105 · 2025: $97.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $400.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $147.13 | 2023-2024 | Recorlev |
| Horizon Therapeutics Plc | $119.39 | 2022 | |
| Sanofi-Aventis U.S. LLC | $69.37 | 2024-2025 | |
| Lilly USA, LLC | $67.36 | 2022-2023 | Jardiance |
| Medtronic, INC. | $49.51 | 2022-2023 | Intellis Adaptivestim |
| Amgen INC. | $36.41 | 2024-2025 | Tepezza, Evenity |
| Rgh Enterprises LLC | $30.33 | 2025 | |
| Janssen Pharmaceuticals, INC | $23.92 | 2019 | |
| Averitas Pharma INC. | $21.29 | 2025 | Qutenza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.77 | 2019 | |
| Mannkind Corporation | $16.82 | 2023 | Afrezza |
| Ultragenyx Pharmaceutical INC. | $13.73 | 2023 | |
| Becton, Dickinson and Company | $13.39 | 2020 | |
| Amarin Pharma, INC. | $12.99 | 2020 | |
| Cequr Corporation | $7.05 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.